Search hospitals > Texas > Fort Worth
UT Southwestern/Simmons Cancer Center-Fort Worth
Claim this profileFort Worth, Texas 76104
Global Leader in Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Bladder Cancer
Conducts research for Adenocarcinoma
76 reported clinical trials
27 medical researchers
Summary
UT Southwestern/Simmons Cancer Center-Fort Worth is a medical facility located in Fort Worth, Texas. This center is recognized for care of Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Bladder Cancer, Adenocarcinoma and other specialties. UT Southwestern/Simmons Cancer Center-Fort Worth is involved with conducting 76 clinical trials across 228 conditions. There are 27 research doctors associated with this hospital, such as David Miller, MD, Suzanne M. Cole, Syed M. Kazmi, and David Gerber, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
David Miller, MDParkland Memorial Hospital2 years of reported clinical research
Expert in Cancer
Studies Ovarian Cancer
20 reported clinical trials
39 drugs studied
Suzanne M. ColeUT Southwestern/Simmons Cancer Center-Dallas4 years of reported clinical research
Expert in Cancer
Studies Bladder Cancer
16 reported clinical trials
38 drugs studied
Syed M. KazmiUT Southwestern/Simmons Cancer Center-Dallas1 year of reported clinical research
Expert in Colorectal Cancer
Studies Colon Cancer
17 reported clinical trials
33 drugs studied
David Gerber, MDUT Southwestern/Simmons Cancer Center-Dallas9 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
16 drugs studied
Clinical Trials running at UT Southwestern/Simmons Cancer Center-Fort Worth
Breast Cancer
Renal Cell Carcinoma
Prostate Cancer
Cancer
Bladder Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Rectal Cancer
Colon Cancer
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at UT Southwestern/Simmons Cancer Center-Fort Worth?
UT Southwestern/Simmons Cancer Center-Fort Worth is a medical facility located in Fort Worth, Texas. This center is recognized for care of Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Bladder Cancer, Adenocarcinoma and other specialties. UT Southwestern/Simmons Cancer Center-Fort Worth is involved with conducting 76 clinical trials across 228 conditions. There are 27 research doctors associated with this hospital, such as David Miller, MD, Suzanne M. Cole, Syed M. Kazmi, and David Gerber, MD.